DataVXAdvanced Healthcare MaterialsPaper
journal article·2016-05Open access

Syndecan‐4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes

Subhamoy Das, Anthony J. Monteforte, Gunjan Singh, Marjan Majid, Michael B. Sherman, Andrew K. Dunn, Aaron B. Baker

Advanced Healthcare Materials· Volume 5· Issue 9
Publisher pageOpen full text
Source abstract

Abstract

Delivering syndecan-4 with FGF-2 improves the effectiveness of FGF-2 therapy for ischemia in the diabetic disease state. The syndecan-4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan-4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Angiogenesis and VEGF in Cancer · Proteoglycans and glycosaminoglycans research · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering University of Texas at Austin Austin TX USA

Sealy Center for Structural Biology and Molecular Biophysics University of Texas Medical Branch at Galveston Galveston TX USA

Institute for Cellular and Molecular Biology University of Texas at Austin Austin TX USA

Institute for Computational Engineering and Sciences (ICES) University of Texas at Austin Austin TX USA

Institute for Biomaterials, Drug Delivery and Regenerative Medicine University of Texas at Austin Austin TX USA

Funding

NIH Director's New Innovator · NIH · NSF · American Heart Association · Coulter Foundation

References (20)

Show source-provided references
1. 10.2337/dc12-262510.2337/dc12-2625 ↗
2. 10.1016/j.jacc.2005.09.06510.1016/j.jacc.2005.09.065 ↗
3. 10.1161/01.CIR.0000114519.75433.DD10.1161/01.CIR.0000114519.75433.DD ↗
4. 10.1038/nrcardio.2011.8110.1038/nrcardio.2011.81 ↗
5. 10.1016/S0140-6736(02)08937-710.1016/S0140-6736(02)08937-7 ↗
6. 10.1016/S0735-1097(00)00882-210.1016/S0735-1097(00)00882-2 ↗
7. 10.1161/CIRCULATIONAHA.104.52955210.1161/CIRCULATIONAHA.104.529552 ↗
8. 10.1038/mt.2008.3310.1038/mt.2008.33 ↗
9. 10.1161/ATVBAHA.110.21955010.1161/ATVBAHA.110.219550 ↗
10. 10.1089/hum.2006.17.68310.1089/hum.2006.17.683 ↗
11. 10.1038/gt.2010.5110.1038/gt.2010.51 ↗
12. 10.1016/j.ahj.2008.06.02510.1016/j.ahj.2008.06.025 ↗
13. 10.1016/j.biomaterials.2013.09.10510.1016/j.biomaterials.2013.09.105 ↗
14. 10.1242/jcs.12463610.1242/jcs.124636 ↗
15. 10.18388/abp.2012_208510.18388/abp.2012_2085 ↗
16. 10.1017/S146239941100194310.1017/S1462399411001943 ↗
17. 10.1128/JVI.01137-0610.1128/JVI.01137-06 ↗
18. 10.1073/pnas.111788510910.1073/pnas.1117885109 ↗
19. 10.1364/OE.16.00197510.1364/OE.16.001975 ↗
20. 10.1186/bcr261510.1186/bcr2615 ↗